Trial Profile
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Tanespimycin (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms TIME-2
- Sponsors Bristol-Myers Squibb; Kosan Biosciences
- 05 Dec 2009 Results were presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009)
- 22 May 2009 Actual initiation date changed from Nov 2008 to Aug 2007 as reported by ClinicalTrials.gov.
- 06 May 2009 Actual end date (1 Feb 2009) added as reported by ClinicalTrials.gov.